Hepatocellular carcinoma

Digestion

Volumn 58, Issue , 1997, Pages 69-75

  Manns, M P ^a   Kubicka, St ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Cirrhosis; Hepatocellular carcinoma; Liver; Orthotopic liver transplantation Hepatitis B and C

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; DOXORUBICIN; EPIRUBICIN;

ASPIRATION BIOPSY; CANCER SCREENING; CONFERENCE PAPER; HEPATITIS B; HEPATITIS C; HUMAN; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; PATHOGENESIS; PRIORITY JOURNAL;

CARCINOMA, HEPATOCELLULAR; COMBINED MODALITY THERAPY; HEPATITIS B; HEPATITIS C; HUMANS; INCIDENCE; LIVER CIRRHOSIS; LIVER NEOPLASMS; MASS SCREENING; PROGNOSIS; RISK FACTORS;

EID: 0030969128     PISSN: 00122823     EISSN: 14219867     Source Type: Journal    
DOI: 10.1159/000201532     Document Type: Article

References (111)

1. Muir C, Waterhouse J, Mack T, Dowell J, Whelan S (eds): Cancer Incidence in live Continents. Geneva. World Health Organization. 1987. I ARC Scientific publ, vol 5.
2. Rustgi VK: Epidemiology of hepatocellular carcinoma. Gastroenterol Clin North Am 1987:16: 545-551.
3. Simonetli RG, Camma C, Fiorello F, Politi F. D'Amico G, Pagliaro I: Hepatocellular carcinoma. A worldwide problem and the major risk factors. Dig Dis Sci 1991:36:962-972
4. Tsukuma H, Hiyama T, Tanaka S, Nakao K, Yabuuchi T, Kitamura T, Nakanishi K, Fujimoto I, Inoue A, Yamazaki H, Kawashima T: Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 1993:328:1797-1801.
5. De Bue C, Strolfolini T, Gaeta GB, Taliani G, Giusti G: Pathogenic factors in cirrhosis with and without hepatocellular carcinoma: A multicenter Italian study. Hepatology 1995:20:1225-1230.
6. Ryder SD, Koskinas J, Rizzi PM, McFarlanc IG, Portman BC, Naoumov NV, Williams R: Hepatocellular carcinoma complicating autoimmune hepatitis: Role of hepatitis C virus. Hepalology 1995:22:718-722.
7. Casporaso N, Romano M, Marino R, de Sio I, Morisco F, Minerva A, Coltorti M: Hepatitis C virus infection is an additive risk factor for development of hepatocellular carcinoma in patients with cirrhosis. J Hepatol 1991; 12:367-371.
8. Simonetti RG, Camma C, Fiorello F, Cottone M, Rapicetta M, Marino L, Fiorentino G, Craxi A, Ciccaglionc A, Giuseppetti R, Strolfolini T, Pagliaro L: Hepatitis C virus infection as a risk factor for hepatocellular carcinoma in patients with cirrhosis. Ann Intern Med 1992:116:97-102.
9. Niederau C, Fischer R, Sonnenberg A, Stremntel W, Trampisch HJ, Strohmeyer G: Survival and cause of death in cirrhotic and noncirrhotic patients with primary hemochromatosis. N Engl J Med 1985:313:1256-1262.
10. Adams PC, Spceehley M, Kertesz AE: Long term survival analysis in hereditary hemochromatosis. Gastroenterology 1991:101:368-372.
11. Eriksson S, Carlson J, Velez R: Risk of cirrhosis and primary liver cancer in a I-antitrypsin deficiency. N F.ngl J Med 1986:314:736-739.
12. Polio J, Enriquez RE, Chow A, Atterburv CE: Hepatocellular carcinoma in Wilson's disease. Case report and review of the literature. J Clin Gastroenterol 1989;11:220-224.
13. Nashan B, Schlitt HJ, Tusch G, Oldhafcr KJ, Ringe B, Wagner S, Pichlmayr R: Biliary malignancies in primary sclerosing cholangitis: Timing for liver transplantation. Hepatology 1996: 23:1105-1111.
14. US Department of Health and Human Services: Sixth Annual Report on Carcinogens. Washington. US Government Printing Office, 1991. publ No 92 12066.
15. Neuberger J, Forman D, Doll R, Williams R: Oral contraceptives and hepatocellular carcinoma. Br Med J 1986:292:1355-1357.
16. La Vccchia C, Negri E, Parazzini F: Oral contraceptives and primary fiver cancer. Br J Cancer 1989:59:460-461.
17. Kew M, Song E, Mohammed A, Hodkinson J: Contraceptive steroids as a risk factor for hepatocellular carcinoma: A case control study in South Africa black women. Hepatology 1990: 11:298-302
18. WHO Collaborative Study: Neoplasia and ste-roidtate (DMPA) and risk of fiver cancer. Int J Cancer 1991:49:182-185.
19. Prentice RL: Epidemiologic data on exogenous hormones and hepatocellular carcinoma and selected other cancers. Prev Med 1991:20: 38-46.
20. Beasley RP, Hwang LY, Lin CC, Chien CS: Hepatocellular carcinoma and hepatitis B virus: A prospective study of 22.707 men in Taiwan. Lancet 1981:ii:1129-1133.
21. Furuta T, Kancmatsu T, Matsumata T, Shirabe K, Yamagata M, Utsunomiya T, Sugimachi K: Clinicopathologic features of hepatocellular carcinoma in young patients. Cancer 1990:66: 2395-2398.
22. Rl-Refaie A, Savage K, Bhattacharya S, Khakoo S, Harrison TJ, El-Balanony M, Soliman FS, Nasr S, Mokhtar N, Amer K, Scheuer PJ, Dhillon AP: HCV-associated hepatocellular carcinoma without cirrhosis. J Hepatol 1996: 24:277-285.
23. Shiratori Y, Shiina S, Imamura M, Kato N, Kanai F, Okudaira T, Teratani T, Tohgo G, Toda N, Ohashi M, Ogura K, Niwa Y, Kawabe T, Omata M: Characteristic difference of hepatocellular carcinoma between hepatitis B- and C-viral infection in Japan. Hepatologv 1995:22: 1027-1033.
24. Bishop JM: Molecular themes in oncogenesis, Cell 1991:64:235-248.
25. Hunter T: Cooperation between oncogenes. Cell 1991:64:249-270.
26. Cross M, Dexter TM: Growth factors in development. transformation and tumorigenesis. Cell 1991:64:271-280.
27. Fearon ER, Vogelstein B: A genetic model for colorectal tumorigenesis. Cell 1990:61:759-767.
28. Schirmacher P, Rogler CE, Diencs HP: Current pathogenic and molecular concepts in viral liver carcinogenesis. Virchows Arch [B] 1993:63:71-89.
29. McMahon G, Davis EF, Huber LJ, Kim Y, Wogan GN: Characterization of c-Ki-ras and N-ras oncogenes in aflatoxin B induced rat liver tumors. Proc Natl Acad Sci USA 1990:87:1104-1108.
30. Chandar N, Lombardi B, Locker J: C-myc gene amplification during hepatocarcinogcnesis by a choline-devoid diet. Proc Natl Acad Sci USA 1989:86:2703-2707.
31. Fourell G, Trepo C, Bouguelerct L, Henglein B, Ponzelto A, Tiollais P, Buendia MA: Frequent activation of N-myc genes by hepdnavirus insertion in woodchuck liver tumors. Nature 1990: 347:294-298.
32. Wang J, Chenivessc X, Henglein B, Brechot C: Hepatitis B virus integration in a cyclin A gene in hepatocellular carcinoma. Nature 1990:348: 555-557.
33. Dejean A, Bouguelerct L, Grzesehik KH, Tiollais P: Hepatitis B virus DNA integration in a sequence homologous to v-crb-A and steroid receptor genes in a hepatocellular carcinoma. Nature 1986:322:70-72.
34. Graei E, Casclman WH, Wells J, Koshy R: In-sertional activation of mevalonate kinase by hepatitis B virus DNA in a human hepatoma cell line. Oncogene 1994:9:81-87.
35. Pasquinelli C, Bhavani K, Chisari FV: Multiple oncogenes and tumor suppressor genes are structurally and functionally intact during hepatocarcinogcnesis in hepatitis virus transgenic mice. Cancer 1992:52:2823-2829.
36. Sever CE, Locker J: Expression of the retinoid acid alpha and beta receptor genes in liver and hepatocellular carcinoma. Mol Carcinog 1991: 4:138-144.
37. Arbuthnot P, Kew M, Fritsch W: c-l’os and c-myc oncoprotein expression in human hepatocellular carcinomas. Anticancer Res 1991:11: 921-924.
38. Gu JR, Hu LF, Cheng YC, Wan DF: Oncogenes in human primary hepatic cancer. J Cell Physiol 1986:4(suppl 1):13-21.
39. Nishida N, Fukada Y, Komeda T, Kita R, Sando T, Furukawa M, Amenomoii M, Shibagaki I, Nakao K, Ikenaga M, Ishizaki K: Amplification and overcxprcssion of cyclin Dl gate in aggressive human hepatocellular carcinoma. Cancer Res 1994:54:3107-3110.
40. Boix L, Rosa JL, Ventura F, Castells A, Bruix J, Rodes J, Bartrons R: c-mct mRNA overexpression in human hepatocellular carcinoma. Hcpatology 1994:19:88-91.
41. Yeh YC, Tsai JF, Chuang LY, Yeh MW, Tsai JH, Florine DL, Tam JP: Elevation of transforming growth factor a and its relationship to the epidermal growth factor and α-fetoprotein levels in patients with hepatocellular carcinoma. Cancer Res 1987:47:896-901.
42. Cariani E, Lasserre C, Seurin D, Hamelin B, Keinenv F, Franco D, Czech MP, Ullrich A, Brechot C: Differential expression of insulin-like growth factor II mRNA in human primary liver cancers, benign liver tumors and liver cirrhosis. Cancer Res 1988:48:6844-6849.
43. Hsu IC, Metcalf RA, Sun T, Welsh JA, Wang NJ, Harris CC: Mutational hot spot in the p53 gene in human hepatocellular carcinomas. Nature 1991:350:427-428.
44. Bressac B, Kew M, Wands J, Ozturk M: Selective G to T mutations of p53genein hepatocellular carcinoma from southern Africa. Nature 1991:350:429-431.
45. Fujimoto Y, Hampton LL, Wirth PJ, Wang NJ, Xie JP, Thorgeirsson SS: Alterations of tumor suppressor genes and allelic losses in human hepatocellular carcinoma in China. Cancer Res 1994:54:281-285.
46. Unsal H, Yakicicr C, Marcais C, Kew M, Volkman M, Zentgraf H, Isselbacher KJ, Ozturk M: Genetic heterogeneity of hepatocellular carcinoma. Proc Natl Acad Sci USA 1994:91:822-826.
47. Aguilar F, Harris CC, Sun T, Hollslein M, Cerutli P: Geographic variation of p53 mutational profile in nonmalignant human liver. Science 1994:264:1317-1319.
48. Aguilar F, Hussain SP, Cerutti P: Aflatoxin Bl induces the transversion of G-T in codon 249 of the p53 tumor suppressor gene in human hepatocyles. Proc Natl Acad Sci USA 1993:90: 8586-8590.
49. Debuire B, Patcrlini P, Pontisso P, Basso G, May E: Analysis of the p53 gene in European hepatocellular carcinomas and hepatoblastomas. Oncogene 1993:8:2303-2306.
50. Volkman M, Hofman WJ, Müler M, Rath U, Otto G, Zentraf H, Galle PR: p53 overexpression is frequent in European hepatocellular carcinoma and largely independent of the codon 249. Oncogene 1994:9:195-204.
51. Kubicka S, Trautwein C, Schrem H, Tillman H, Manns M: Low incidence of p53 mutations in European hepatocellular carcinomas with heterogeneous mutation as a rare event. J Hepatol 1995:23:412-419.
52. Hayashi H, Sugio K, Matsumata T, Adachi F, Takcnaka K, Sugimachi K: The clinical significance of p53 gene mutation in hepatocellular carcinomas from Japan. Hepatology 1995:22: 1702-1707.
53. Schröder CH, Zentgraf H: Hepatitis B virus related hepatocellular carcinoma: Chronicity of infection: The opening to different pathways of malignant transformation? Biochim Biophys Acta" 1990:1032:137-156.
54. Robinson WS: Molecular events in the pathogenesis of hepdnavirus-associatcd hepatoecllu-larcarcinoma. Annu Rev Med 1994:45:297-323.
55. Casclman WH: Transactivalion of cellular gene expression by hepatitis B viral proteins: A possible molecular mechanism of hcpatocarcino-gencsis. J Hepatol 1995:22(suppl):34-37.
56. Kim CM, Koike K, Saito I, Myamura T, Jay G: H Bx gene of hepatitis B virus induces liver cancer in transgenic mice. Nature 1991:351:317-320.
57. Seifer M, Höhne M, Schaefer S, Gerlich WH: In vitro tumorigcnicity of hepatitis B virus DNA and HBx protein. H Hepatol 1991:13:61-65.
58. Seto E, Mitchell PJ, Yen TSB: Transactivation by hepatitis B virus X protein depends on AP-2 and other transcription factors. Nature 1990; 344:72-74.
59. Twu JS, Roden CA, Haseltinc WA, Robinson WS: Identification of a region within the human immunodeficiency virus type I long terminal repeat that is essential for transactivation by the hepatitis B virus gene X. J Virol 1989;63: 2857-2860.
60. Colgrove R, Simon G, Ganem D: Transcriptional activation of homologous and heterologous genes by the hepatitis B virus gene product in cells permissive for viral replication. J Virol 1989:63:4019-4026.
61. Natoli G, Avantaggiati ML, Chirillo P: Induction of the DNA-binding activity of c-jun/c-fos hcterodimers by the hepatitis B virus transactivator pX. Mol Cell Biol 1994:14:989-998.
62. Wu JY, Zhou ZY, Judd A, Cartwright CA, Robinson WS: The hepatitis B virus-encoded transcriptional trans-activator hbx appears to be a novel protein serine/threonine kinase. Cell 1990:63:687-695.
63. Takada S, Kido H, Fukutomi A, Mori T, Koike K: Interaction of hepatitis B virus X protein with a serine protease, tryptase TL2 as an inhibitor. Oncogene 1994:9:341-348.
64. Wang XW, Forrester K, Yeh H, Feitelson MA, Gu JR, Harris CC: Hepatitis B virus X protein inhibits p53 sequence-specific DNA binding, transcriptional activity, and association with transcription factor ERCC3. Proc Nall Acad Sci USA 1994:91:2230-2234.
65. Casclman WH, Mayer M, Kekule AS, Lauer U, Holschneider PH, Koshy R: A novel transactivator is encoded by hepatitis B virus preS/S sequences integrated in human hepatocellular DNA. Proc Natl Acad Sci USA 1990:87:2970-2974.
66. Lauer U, Weiss L, Hofschncider PH, Kelule AS: Transcription factors AP-I, AP-2 and NFkB arc mediators of the II liV preS/S (MHBs) trans-activator effect (abstract). Hepatology 1991:14: 120.
67. Mayer M, Cascltnan WH, Schlütcr V, Sehreck R, Hofschncider PH, Baeuerlc PA: Hepatitis B virus transactivator MHBst: Activation of Ni kII. selective inhibition by antioxidants and integral membrane localization. EMBOJ 1992; 11:2991-3001.
68. Ray BB, Lagging LM, Mahyer K, Steele R, Ray R: Transcriptional regulation of cellular and viral promoters by the hepatitis C virus core protein. Virus Res 1995:37:209-220.
69. Sakamuro D, Furukawa T, Takcgami T: Hepatitis C virus nonstructural protein NS3 transforms Nil I 3T3 cells. J Virol 1995:69:3893-3896.
70. Miller WJ, Federle MP, Campbell WL: Diagnosis and staging of hepatocellular carcinoma. AJR 1991:157:303-306.
71. Takayasu K, Moriyama N, Muramatsu Y, Makuuchi M, Hascgawa H, Okazaki N, Hirohashi S: The diagnosis of small hepatocellular carcinomas: Effecacy of various imaging procedures in 100 patients. AJR 1990:155:49-54.
72. Oi H, Murakami T, Kim T, Matsushita M, Kishimoto H, Nakamura H: Dynamic MR and early-phase helical CT for detecting small in-trahepatic métastasés of hepatocellular carcinoma. AJR 1996:166:369-374.
73. Paraskcvopoulos JA: Management options for primary hepatocellular carcinoma. Acta Oncol 1994:33:895-900.
74. Venook AP: Treatment of hepatocellular carcinoma: Too many options? J Clin Oncol 1994: 12:1323-1334.
75. Makuuchi M, Kosuge T, Takayama T, Yamazaki S, Kakazu T, Miyagawa S, Kawasaki S: Surgery for small liver cancers. Semin Sure Oncol 1993:9:298-304.
76. Pichlmayr R, Weiman A, Ringe B: Indications for liver transplantation in hepatobiliary malignancy. Hepatology 1994:20(suppl):30-40.
77. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvierenti A, Bozzctti F, Montalto F, Anttnatuna M, Morabito A, Gennari L: Liver transplantation lor the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996:334:693-699.
78. Bismuth H, Chiche L, Adam R, Castaing D, Diamond T, Dennison A: Liver resection versus transplantation for hepatocellular carcinoma in cirrhotic patients. Ann Surg 1993:218:145-151.
79. Carr BI, Selby R, Madariaga J, Iwatsuki S, Starzl TE: Prolonged survival after liver transplantation and cancer chemotherapy for ad-vanced-stage hepatocellular carcinoma. Transplant Proc 1993:25:1128-1129.
80. Stone MJ, Klintmalm GBG, Poller D, Husberg BS, Mcnnel RG, Ramsay MAE, Flemens EE, Goldstein RM: Neoadjuvant chemotherapy and liver transplantation for hepatocellular carcinoma: A pilot study in 20 patients. Gastroenterology 1993:104:196-202.
81. Cherqui D, Piedbois P, Pierga JY, Duvoux C, Vavasseur D, Van-Nhieu JT, LeBourgeois IP, Dhumeaux D: Multimodal adjuvant treatment and liver transplantation for advanced hepatocellular carcinoma. Cancer 1994:73:2721-2726.
82. Olthol TKM, Rosove MH, Shacklcton CR, Imagawa DK, Farmer DG, Northcross P, Pakrasi AL, Martin P, Goldstein LI, Shaked A, Busuttil RW: Adjuvant chemotherapy improves survival after liver transplantation for hepatocellular carcinoma. Ann Surg 1994:221:734-743.
83. Rizzi PM, Ryder SD, Ramage IK, Ganc E, Karani J, Heaton N, Portmann B, Tan KC, Williams R: Neoadjuvant chemotherapy after liver transplantation for hepatocellular carcinoma. Transplant Proc 1994:26:3568-3569.
84. Schwartz ME, Sung M, Mor E, Fisher A, Popescu I, Fiel I, Sheiner P, Emre S, Guy S, Miller CM: A multidisciplinary approach to hepatocellular carcinoma in patients with cirrhosis. J Am Coll Surg 1995:180:596-603.
85. Livraghi T, Bolondi L, Lazzaroni S, Marin G, Morabito A, Rapaccini GL, Salmi A, Torzilli G: Percutaneous ethanol injection in the treatment of hepatocellular carcinoma in cirrhosis. Cancer 1992:69:925-929.
86. Shiina S, Tagawa K, Niwa Y, Linuma T, Komatsu Y, Yoshiura K, Ilamada E, Takahashi M, Shiratori Y, Terano A, Omata M, Kawauchi N, Inoue H: Percutaneous ethanol injection therapy for hepatocellular carcinoma: Results in 146 patients. AJR 1993:160:1023-1028.
87. Castells A, Bruix J, Bru C, Fuster J, Vilana R, Navasa M, Ayuso C, Boix L, Visa J, Rodes J: Treatment of small hepatocellular carcinoma in cirrhotic patients: A cohort study comparing surgical resection and percutaneous ethanol injection. Hepatology 1993:18:1121-1126.
88. Olmishi K, Nomura F, Ito S, Fujiwara K: Prognosis of small hepatocellular carcinoma (less than 3 cm) tiller percutaneous acetic acid injection: Study of 91 cases. Hepatology 1996:23: 994-1002.
89. Vilaseea J, Guerdia J, Bacardi R, Monne J: Doxorubicin for liver cancer. Lancet 1978:i: 1367
90. Lai CL, Wu PC, Chan GC, Lok ASF, Lin HJ; Doxorubicin versus no antilumour therapy in inoperable hepatocellular carcinoma. Cancer 1988:62:479-483.
91. Nerenstone SR, Ihde DC, Friedman MA: Clinical trials in primary hepatocellular carcinoma: Current status and future directions. Cancer Treat Rev 1988:15:1-31.
92. Lotze MT, Flickingcr JC, Carr BL: Hepatobiliary neoplasms: in De Vita VT Jr. Heilman S. Rosenberg SA (eds): Cancer, Principles and Practice of Oncology, ed 4 Philadelphia. Lippincott, 1993. pp 883-914.
93. Bronowieki IP, Vetter D, Dumas F, Boudjcma K, Bader R, Weiss AM, Wenger JJ, Boissel P, Bigard AM, Dolfoel M: Transcatheter oily chemoembolization for hepatocellular carcinoma. A 4-year study of 127 French patients. Cancer 1994:74:16-24.
94. Bruix J, Castells A, Montanya X, Calvel X, Bru C, Ayuso C, Jover L, Garcia L, Vilana R, Boix L, Rodes J: Phase II study of transarterial embolization in European patients with hepatocellular carcinoma: Need for controlled trials. Hepatology 1994:20:643-650.
95. Mondazzi L, Bottelli R, Brambilla G, Rantpoldi A, Rezakovic I, Zavaglia C, Alberti A, Ideo G: Transarterial oily chemoembolization for the treatment of hepatocellular carcinoma: A multivariate analysis of prognostic factors. Hepatology 1994:19:1115-1123.
96. Pati YZ, Charnsangavcj C, Yolfc B, Smith R, Lawrence D, Chuang V, Carrasco H, Roh M, Chase J, Fischer H, Jones D, Levin B: Hepatic arterial infusion of Floxuridine. Lcucovorin. Doxorubicin, and Cisplatin for hepatocellular carcinoma: Effects of hepatitis B and C viral infection on drug toxicity and patients survival. J Clin Oncol 1994:12:1204-1211.
97. Stefanini GF, Amorali P, Biselli M, Mttcci F, Celi A, Alienti V, Roversi R, Rossi C, Re G, Gasbarrini G: Efficacy of transarterial targeted treatments on survival of patients with hepatocellular carcinoma. An Italian experience. Cancer 1995:75:2427-2434.
98. Ryder SD, Rizzi PM, Metivier E, Karani J, Williams R: Chemoembolization with lipiodol and doxorubicin: Applicability in British patients with hepatocellular carcinoma. Gut 1996:38:125-128.
99. Groupe d etude et de traitcment du carcinome hépatocellulaire: A comparison of lipiodol chemoembolization and conservative treatment lor unrcsectable hepatocellular carcinoma. N Engl J Med 1995:332:1256-1261.
100. Ginsberg GM, Shouval D: Cost-benefit analysis of a national neonatal inoculation programme against hepatitis B in an area of intermediate cndemicily. J Epidemiol Commuti Health 1992:46:587-594.
101. Niederau C, Fischer R, Sonncnberg A, Stremmel W, Trampisch HJ, Strohmeyer G: Survival and causes of death in cirrhotic and non-cirrhotic patients with primary hemochromatosis. N Engl J Med 1985:313:1256-1262.
102. Niederau C, Fischer R, Piirschel A, Sliemmel W, Haussinger D, Strohmeyer G: Long-term survival in patients with hereditary hemochromatosis. Gastroenterology 1996:110:1107-1119.
103. Nishiguchi S, Kuroki T, Nakatani S, Morimmo H, Takeda T, Nakajima S, Shiomi S, Seki S, Kobayashi K, Olani S: Randomised trial of effects of imerlcron-ot on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995:346:1051-1055.
104. Mazzetta G, Accogli E, Sottili S, Fesli D, Orsini M, Salzella A, Novelli V, Cipolla A, Fabbri C, Pczzoli A, Roda E: Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis. J Hepatol 1996: 24:141-147.
105. Mulo Y, Moriwaki H, Ninomiya M, Adachi S, Saito A, Takasaki KT, Tanaka T, Tsurumi K, Okuno M, Tomita E, Nakamura T, Kojima T, for the Hepatoma Prevention Study Group: Prevention of second primary tumors by an acyclic retinoid, polyprcnoic acid, in patients with hepatocellular carcinoma. N Engl J Med 1996:334:1561-1567.
106. Sheu JC, Sung JL, Chen DS, Lai MY, Wang TIL, Yu JY, Yang PM, Chuang CN, Yang PC, Lee CS: Early detection of hepatocellular carcinoma by real-time ultrasonograpy. A prospective study. Cancer 1985:56:660-666.
107. Cottone M, Turri M, Parisi P, Orlando A, Fiorentino G, Virdone R, Fusco G, Grasso R, Simonetti RG, Pagliaro L: Screening for hepatocellular carcinoma in patients with child's A cirrhosis: An 8-year prospective study by ultrasound and alphalctoprolein. J I lepatol 1994:21:1029-1034.
108. Colombo M, De Franchia R, Ninno ED, Sangiovanni A, De Facio C, Tommasini M, Donato ME, Piva A, Di Carlo V, Dioguardi N: Hepatocellular carcinoma in Italian patients with cirrhosis. N Engl J Med 1991:325:675-680.
109. Oka H, Tarnori A, Kuroki T, Kobavashi K, Yamamoto S: Prospective study of α-fetoprotein in cirrhotic patients monitored for development ofhepatocellular carcinoma. Hcpatology 1994:19:61-66.
110. Paleron D, Gamie N, Triehel JC, Aurousseau MH, Mal F, Meicler C, Coderc E, Reboullet P, Beaugrand M: Prospective study of screening for hepatocellular carcinoma in Caucasian patients with cirrhosis. J Hepatol 1994:20:65-71.
111. Sherman M, Peltekian KM, Lee C: Screening for hepatocellular carcinoma in chronic carriers of hepatitis B virus: Incidence and prevalence of hepatocellular carcinoma in a North American urban population. Hepalology 1995:22:432-438.